SELLAS Reports Positive Phase 3 AML Trial Data for Cancer Vaccine GPS
SELLAS Life Sciences announced statistically significant overall survival improvement in a Phase 3 AML trial of GPS. The result validates a potential breakthrough in oncology, driving significant market relevance for the biopharmaceutical.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed